Resultado de búsqueda
Hace 22 horas · Silo Pharma, Inc. (NASDAQ:SILO) ha mostrado su compromiso con el avance de su principal candidato a fármaco, SPC-15, con el reciente acuerdo de licencia exclusiva con la Universidad de Columbia.
Hace 22 horas · Silo Pharma, Inc. (NASDAQ:SILO) has shown a commitment to advancing its primary drug candidate, SPC-15, with the recent exclusive licensing deal with Columbia University. The company's strategic initiatives are reflected in its financial metrics and management activities. Notably, Silo Pharma's management has been proactively engaging in share ...
Hace 22 horas · Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders ...
Hace 22 horas · Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders ...
Hace 5 horas · Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into a license agreement with Columbia University.The agreement, which is exclusive and global, outlines plans to further develop, manufacture and commercialize Silo’s lead drug ...
Hace 10 horas · Extensive Issued and Pending IP Patent Applications Acquired with License Agreement SARASOTA, FL, July 08, 2024 -- Silo Pharma, Inc. , a developmental stage biopharmaceutical company focused on...
Hace 22 horas · Silo's two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (“MS”).
